Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gefitinib Plus CIK Cells in Advanced Adenocarcinoma NSCLC
NCT01871480Phase 2Terminated
- Sponsor
- Kunming Medical University
- Start
- May 2013
- Primary completion
- Nov 2015
- Modality
- Allogeneic CAR-T, Tumor-Infiltrating Lymphocytes (TILs), TCR-Engineered T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of unmodified CIK in non-small cell lung cancer (NSCLC), sponsored by Kunming Medical University. Started May 2013; status: terminated.
02
Drugs
unmodified CIK
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT01871480.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01871480.